Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Incyte Corporation is conducting a Phase 3 clinical study titled ‘A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)’. The study aims to compare the efficacy and safety of pemigatinib against the standard chemotherapy regimen of gemcitabine plus cisplatin in treating patients with a specific type of bile duct cancer.
The study tests the drug pemigatinib, an oral medication administered daily, against gemcitabine and cisplatin, which are given intravenously. Pemigatinib is designed to target FGFR2 rearrangements in cholangiocarcinoma, offering a potential alternative to traditional chemotherapy.
This interventional study is randomized with a parallel assignment of participants, meaning patients are randomly assigned to receive either pemigatinib or the chemotherapy combination. The study is open-label, so both researchers and participants know which treatment is being administered. The primary goal is to assess treatment effectiveness.
The study began on June 3, 2019, and is currently active but not recruiting new participants. The last update was submitted on July 1, 2025. These dates indicate the study’s ongoing nature and the timeline for data collection and analysis.
The outcome of this study could significantly impact Incyte Corporation’s stock performance, as successful results might lead to increased investor confidence and market share in the oncology sector. The study’s findings could also influence the competitive landscape, particularly if pemigatinib proves to be a more effective treatment option.
The study is ongoing, and further details can be found on the ClinicalTrials portal.